Price$98.24+1.22 (+1.26%)
02:30 PM07:45 PM
News · 26 weeks25-43%
2025-10-262026-04-19
Mix1590d
- Insider6(40%)
- SEC Filings4(27%)
- Other3(20%)
- Leadership1(7%)
- Dividends1(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by President and CEO Kadia Siddhartha4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kadia Siddhartha3 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- PRMESA LABS DECLARES QUARTERLY DIVIDENDLAKEWOOD, Colo., April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase pa
- INSIDERSEC Form 4 filed by Owens Gary M4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mesa Laboratories Inc.SCHEDULE 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
- SECMesa Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
- INSIDERDirector Ladiwala Shiraz Shabanali bought $252,805 worth of shares (3,500 units at $72.23), increasing direct ownership by 70% to 8,523 units (SEC Form 4)4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- INSIDERDirector Capone Mark Christopher bought $99,331 worth of shares (1,301 units at $76.35), increasing direct ownership by 61% to 3,429 units (SEC Form 4)4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- INSIDERDirector Tripeny R Tony bought $99,940 worth of shares (1,315 units at $76.00), increasing direct ownership by 32% to 5,398 units (SEC Form 4)4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- SECMesa Laboratories Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
- PRMesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEOLAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition. "Gary has served as Mesa's CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the company's foundation, and the implementation of The Mesa Way business system," said John Sullivan, Chair of the Board. "We are grateful for his leadership and wish him continued success." T
- PRAs Worker Safety Scrutiny Intensifies, Mesa Labs Reinforces Why Primary Standard Calibration Is the Only Line of DefenseLAKEWOOD, Colo., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety professionals confront rising regulatory scrutiny and a generational workforce transition that threatens the integrity of workplace exposure monitoring. Across industries from pharmaceutical manufacturing to construction, worker safety depends on the accuracy of air sampling pumps used to measure exposure to hazardous substances. Those pump
- SECSEC Form 10-Q filed by Mesa Laboratories Inc.10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
- SECMesa Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
- PRMesa Labs Announces Third Quarter ResultsLAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q26") ended December 31, 2025 (amounts in thousands). 3Q26 Financial Summary – (comparisons are versus the same year ago period Revenues increased 3.6%Non-GAAP organic and core organic revenues1 growth was 3.6% and 1.2%, respectivelyNon-GAAP organic revenues growth excluding CG China revenues (entirely diagnostics) was 5.7%Operating income increased 38.0% to $7,975 Non-GAAP adjusted operating income ("AOI") exclu
- PRMESA LABS DECLARES QUARTERLY DIVIDENDLAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
- PRMesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast of the presentation will be accessible here and on the Events & Presentations section of Mesa Lab's Investor Relations website at https://investors.mesalabs.com/. An archived replay of the webcast will be available through the same
- INSIDERDirector Sullivan John James gifted 2,000 shares, decreasing direct ownership by 7% to 25,282 units (SEC Form 4)4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
- PRMesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern Time (ET) on Tuesday, February 3, 2026. About Mesa LaboratoriesMesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Mesa Laboratories ContactsGary Owen
- PRMesa Laboratories, Inc. to Participate in Upcoming Investor ConferencesLAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcoming conferences: Raymond James Napa Valley Small Cap SymposiumFormat: 1x1 Meetings Date: Monday, November 17, 2025Jefferies London Healthcare Conference Format: Fireside chatDate: Thursday, November 20, 2025Time: 12:00 p.m. GMTWebcast: Click Here 8th Annual Evercore Healthcare ConferenceFormat: Fireside chat Date: Wednesday, December 3, 2025Time: 2:10 p.m. ET The Jefferies London Healthcare Conference fireside chat will be accessible via live webcast here, and a replay will be available on th
- SECSEC Form 10-Q filed by Mesa Laboratories Inc.10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
- SECMesa Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
- PRMesa Labs Announces Second Quarter ResultsLAKEWOOD, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter ("2Q26") ended September 30, 2025 (amounts in thousands). Financial Summary – 2Q26 versus the same year ago period Revenues increased 5.0%Non-GAAP core organic revenues1 growth was 3.7%Operating income increased 34.7% to $4,724 Non-GAAP adjusted operating income ("AOI") excluding unusual items2 increased 6.1% and was 25.1% as a percentage of revenues We operate a diversified business across four divisions: Ster
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mesa Laboratories Inc.SCHEDULE 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
- INSIDERPresident and CEO Owens Gary M converted options into 11,558 shares, increasing direct ownership by 22% to 64,135 units (SEC Form 4)4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)